The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.

Recombinant microorganisms, pharmaceutical compositions thereof, and methods of protein display on the cell surface of the microorganisms are disclosed.

The present disclosure relates to specific delivery of a lipid-peptide conjugate to immune cells ex vivo or in vivo for decreasing or increasing an immune response against therapeutically relevant antigens. The lipid-peptide-antigen is comprised of a peptide, a lipid, and a functional group that is degraded in a biological environment within cells to release the peptide for MHC presentation and provides a more efficient presentation of antigen epitopes by antigen presenting cells than peptide epitopes alone.

Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ΔNPM1 positive haematological malignancy. Corresponding methods and uses are also provided.

Disclosed herein are compositions and methods for cancer immunotherapy, and more particularly immune cells loaded with protein clusters and/or immunostimulatory fusion molecules (IFMs), in combination with an inhibitor of a checkpoint inhibitor.

The invention concerns a modified bacteria; a pharmaceutical composition comprising same; and a method of preventing or treating disease particularly, but not exclusively, cancer or an infectious disease using same.

Provided is a method of preparing a personalized immunogenic composition, which may be prepared by obtaining genetic sequences from a liquid biopsy, comparing the genetic sequences to a wild-type reference genome to identify mutant sequences, selecting epitopes from the mutant sequences, producing the peptides encoded by the selected epitopes, and incorporating the produced peptides into an immunogenic composition. Obtaining the genetic sequences may include next-generation sequencing of genetic material that has been enriched from the liquid biopsy. Deep sequencing (average coverage of 10,000× and above) may be used to detect gene mutations with rare frequencies. Immunogenicity of selected epitopes may be predicted using various in silico methods and epitopes used in an immunogenic composition may be selected from those selected epitopes with high binding amity to HLA. An immunogenic composition prepared using these methods may be administered to a subject.

The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector, wherein the Salmonella Typhi vector has been engineered to express one or more cancer antigens. In some aspects the vector has been engineered to express an outer membrane folding protein BamA or a fragment or variant thereof; and a lipid A deacylase PagL or a fragment or variant thereof, wherein the Salmonella Typhi vector is capable of delivering the antigen to a mucosal tissue or subcutaneously to dendritic cells via an outer membrane vesicle when administered to a subject.

The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making bacterial and viral vaccines